Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Lancet Oncol

Retrieve available abstracts of 68 articles:
HTML format
Text format



Single Articles


    April 2017
  1. FOUAD TM, Barrera AM, Reuben JM, Lucci A, et al
    Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.
    Lancet Oncol. 2017;18:e228-e232.
    PubMed     Text format     Abstract available


    March 2017
  2. BURKI TK
    Sacituzumab govitecan activity in advanced breast cancer.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30232.
    PubMed     Text format    


  3. RUGO HS, Seneviratne L, Beck JT, Glaspy JA, et al
    Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
    Lancet Oncol. 2017 Mar 14. pii: S1470-2045(17)30109.
    PubMed     Text format     Abstract available


    February 2017
  4. MAYOR S
    Service review: improving breast cancer care in Tanzania.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30160.
    PubMed     Text format    


  5. MATHEW A, Brufsky A
    Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30150.
    PubMed     Text format    


  6. BROWER V
    Scalp cooling and hair loss during breast cancer chemotherapy.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30158.
    PubMed     Text format    


  7. LLOMBART-CUSSAC A, Cortes J, Pare L, Galvan P, et al
    HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30021.
    PubMed     Text format     Abstract available


  8. ZHANG P, Sun T, Zhang Q, Yuan Z, et al
    Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
    Lancet Oncol. 2017 Feb 10. pii: S1470-2045(17)30088.
    PubMed     Text format     Abstract available


  9. BROWER V
    Letrozole not superior to anastrozole for early breast cancer.
    Lancet Oncol. 2017 Feb 2. pii: S1470-2045(17)30081.
    PubMed     Text format    


    December 2016
  10. TANDAY S
    Duloxetine lessens joint pain in early-stage breast cancer.
    Lancet Oncol. 2016 Dec 15. pii: S1470-2045(16)30656.
    PubMed     Text format    


  11. GOURD K
    San Antonio Breast Cancer Symposium 2016.
    Lancet Oncol. 2016 Dec 15. pii: S1470-2045(16)30658.
    PubMed     Text format    


  12. BURKI TK
    Incidence of breast cancer in women with type 2 diabetes.
    Lancet Oncol. 2016;17:e523.
    PubMed     Text format    


    November 2016
  13. BURKI TK
    Palbociclib improves survival in advanced breast cancer.
    Lancet Oncol. 2016 Nov 24. pii: S1470-2045(16)30619.
    PubMed     Text format    


  14. VENKATESAN P
    Trastuzumab emtansine for HER2-positive breast cancer.
    Lancet Oncol. 2016 Nov 17. pii: S1470-2045(16)30589.
    PubMed     Text format    


    October 2016
  15. BURKI TK
    Ribociclib in HR-positive, HER2-negative breast cancer.
    Lancet Oncol. 2016 Oct 13. pii: S1470-2045(16)30502.
    PubMed     Text format    


  16. JATOI I, Benson JR, Toi M
    De-escalation of axillary surgery in early breast cancer.
    Lancet Oncol. 2016;17:e430-e441.
    PubMed     Text format     Abstract available


    September 2016
  17. ASDOURIAN MS, Skolny MN, Brunelle C, Seward CE, et al
    Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis.
    Lancet Oncol. 2016;17:e392-405.
    PubMed     Text format     Abstract available


    August 2016
  18. BALAKRISHNAN VS
    Physical exercise might affect breast cancer outcomes.
    Lancet Oncol. 2016 Aug 11. pii: S1470-2045(16)30389.
    PubMed     Text format    


  19. BRUFSKY A
    Is there room for bevacizumab in metastatic breast cancer?
    Lancet Oncol. 2016 Aug 5. pii: S1470-2045(16)30295.
    PubMed     Text format    


  20. ZIELINSKI C, Lang I, Inbar M, Kahan Z, et al
    Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Lancet Oncol. 2016 Aug 5. pii: S1470-2045(16)30154.
    PubMed     Text format     Abstract available


    July 2016
  21. TANDAY S
    IVF treatment not linked to breast cancer.
    Lancet Oncol. 2016 Jul 21. pii: S1470-2045(16)30371.
    PubMed     Text format    


  22. BAKER H
    Adaptive treatments show promise in breast cancer.
    Lancet Oncol. 2016 Jul 14. pii: S1470-2045(16)30315.
    PubMed     Text format    


  23. GHISLAIN I, Zikos E, Coens C, Quinten C, et al
    Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.
    Lancet Oncol. 2016;17:e294-304.
    PubMed     Text format     Abstract available


    June 2016
  24. BERNARDI D, Macaskill P, Pellegrini M, Valentini M, et al
    Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study.
    Lancet Oncol. 2016 Jun 23. pii: S1470-2045(16)30101.
    PubMed     Text format     Abstract available


  25. VAN MAAREN MC, de Munck L, de Bock GH, Jobsen JJ, et al
    10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.
    Lancet Oncol. 2016 Jun 22. pii: S1470-2045(16)30067.
    PubMed     Text format     Abstract available


  26. BERTUCCI F, Viens P, Birnbaum D
    SPAG5: the ultimate marker of proliferation in early breast cancer?
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30092.
    PubMed     Text format    


  27. ABDEL-FATAH TM, Agarwal D, Liu DX, Russell R, et al
    SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)00174.
    PubMed     Text format     Abstract available


    May 2016
  28. GIANNI L, Pienkowski T, Im YH, Tseng LM, et al
    5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Lancet Oncol. 2016 May 11. pii: S1470-2045(16)00163.
    PubMed     Text format     Abstract available


  29. BACHELOT T, Campone M, Tredan O
    PI3K targeting in breast cancer: the end of the beginning?
    Lancet Oncol. 2016 May 4. pii: S1470-2045(16)00148.
    PubMed     Text format    


  30. KROP IE, Mayer IA, Ganju V, Dickler M, et al
    Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2016 May 4. pii: S1470-2045(16)00106.
    PubMed     Text format     Abstract available


  31. CHAN A, Buyse M, Yao B
    Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply.
    Lancet Oncol. 2016;17:e176-7.
    PubMed     Text format    


  32. HASEGAWA T, Uno H, Wei LJ
    Neratinib after trastuzumab in patients with HER2-positive breast cancer.
    Lancet Oncol. 2016;17:e176.
    PubMed     Text format    


    April 2016
  33. BURKI TK
    Trastuzumab cardiotoxicity in early-stage breast cancer.
    Lancet Oncol. 2016 Apr 28. pii: S1470-2045(16)30114.
    PubMed     Text format    


    March 2016
  34. BERTUCCI F, Fekih M, Autret A, Petit T, et al
    Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2016 Mar 28. pii: S1470-2045(16)00011.
    PubMed     Text format     Abstract available


  35. CRISTOFANILLI M
    Inflammatory breast cancer: a new approach.
    Lancet Oncol. 2016 Mar 28. pii: S1470-2045(16)00064.
    PubMed     Text format    


  36. BURKI TK
    Genomic profiling of male breast cancer.
    Lancet Oncol. 2016 Mar 17. pii: S1470-2045(16)00179.
    PubMed     Text format    


  37. CRISTOFANILLI M, Turner NC, Bondarenko I, Ro J, et al
    Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind,
    Lancet Oncol. 2016 Mar 2. pii: S1470-2045(15)00613.
    PubMed     Text format     Abstract available


  38. DUFFY SW
    DCIS and invasive interval breast cancer - Author's reply.
    Lancet Oncol. 2016;17:e88-9.
    PubMed     Text format    


  39. FOUCAR E
    DCIS and invasive interval breast cancer.
    Lancet Oncol. 2016;17:e87.
    PubMed     Text format    


  40. NAROD SA, Sopik V, Sun P
    DCIS and invasive interval breast cancer.
    Lancet Oncol. 2016;17:e87-8.
    PubMed     Text format    


    February 2016
  41. RUGO HS, Chien AJ
    HER2-positive breast cancer: is more treatment better?
    Lancet Oncol. 2016 Feb 10. pii: S1470-2045(15)00623.
    PubMed     Text format    


  42. CHAN A, Delaloge S, Holmes FA, Moy B, et al
    Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2016 Feb 10. pii: S1470-2045(15)00551.
    PubMed     Text format     Abstract available


  43. COLLEONI M
    Neoadjuvant nab-paclitaxel in breast cancer: trial results and patient care.
    Lancet Oncol. 2016 Feb 8. pii: S1470-2045(15)00566.
    PubMed     Text format    


  44. UNTCH M, Jackisch C, Schneeweiss A, Conrad B, et al
    Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
    Lancet Oncol. 2016 Feb 8. pii: S1470-2045(15)00542.
    PubMed     Text format     Abstract available


  45. BURKI TK
    Happygram.
    Lancet Oncol. 2016;17:152.
    PubMed     Text format    


  46. BAKER H
    Familial risk in patients with carcinoma of unknown primary.
    Lancet Oncol. 2016;17:e48.
    PubMed     Text format    


    January 2016
  47. KROP IE
    Lessons from breast cancer trials of HER2-kinase inhibitors.
    Lancet Oncol. 2016 Jan 25. pii: S1470-2045(16)00004.
    PubMed     Text format    


  48. HARBECK N, Huang CS, Hurvitz S, Yeh DC, et al
    Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
    Lancet Oncol. 2016 Jan 25. pii: S1470-2045(15)00540.
    PubMed     Text format     Abstract available


  49. EVANS A
    Detection of DCIS and reduced invasive interval cancers.
    Lancet Oncol. 2016;17:14-5.
    PubMed     Text format    


  50. BALAKRISHNAN VS
    Patient risk factors versus physician guidelines for anti-emetics.
    Lancet Oncol. 2016;17:e7.
    PubMed     Text format    


    December 2015
  51. ELSADA A, Doss S, Robertson J, Adam EJ, et al
    NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer.
    Lancet Oncol. 2015 Dec 15. pii: S1470-2045(15)00587.
    PubMed     Text format    


  52. BAKER H
    Use of antidepressants and breast cancer recurrence.
    Lancet Oncol. 2015 Dec 10. pii: S1470-2045(15)00575.
    PubMed     Text format    


  53. VENKATESAN P
    Internal mammary node irradiation and breast cancer survival.
    Lancet Oncol. 2015 Dec 3. pii: S1470-2045(15)00561.
    PubMed     Text format    


  54. BADWE R, Gupta S, Nair N, Parmar V, et al
    Survival of patients with metastatic breast cancer with or without locoregional therapy - Authors' reply.
    Lancet Oncol. 2015;16:e587-8.
    PubMed     Text format    


  55. BISWAS B, Dabkara D, Ganguly S
    Survival of patients with metastatic breast cancer with or without locoregional therapy.
    Lancet Oncol. 2015;16:e586-7.
    PubMed     Text format    


  56. HONDA K, Gyawali B, Ando Y
    Survival of patients with metastatic breast cancer with or without locoregional therapy.
    Lancet Oncol. 2015;16:e586.
    PubMed     Text format    


  57. GOUNARIS I
    Survival of patients with metastatic breast cancer with or without locoregional therapy.
    Lancet Oncol. 2015;16:e585.
    PubMed     Text format    


  58. FOUAD TM
    Survival of patients with metastatic breast cancer with or without locoregional therapy.
    Lancet Oncol. 2015;16:e585-6.
    PubMed     Text format    


    November 2015
  59. TAKASHIMA T, Mukai H, Hara F, Matsubara N, et al
    Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Lancet Oncol. 2015 Nov 23. pii: S1470-2045(15)00411.
    PubMed     Text format     Abstract available


  60. MARTIN M, Lopez-Tarruella S
    S1 versus taxanes for HER2-negative metastatic breast cancer.
    Lancet Oncol. 2015 Nov 23. pii: S1470-2045(15)00470.
    PubMed     Text format    


  61. LIN NU
    Better treatments needed for breast cancer brain metastases.
    Lancet Oncol. 2015 Nov 16. pii: S1470-2045(15)00477.
    PubMed     Text format    


  62. CORTES J, Dieras V, Ro J, Barriere J, et al
    Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase
    Lancet Oncol. 2015 Nov 16. pii: S1470-2045(15)00373.
    PubMed     Text format     Abstract available


  63. WOODWARD WA
    Inflammatory breast cancer: unique biological and therapeutic considerations.
    Lancet Oncol. 2015;16:e568-76.
    PubMed     Text format     Abstract available


  64. BAKER H
    21-gene assay identifies patients who can avoid chemotherapy.
    Lancet Oncol. 2015;16:e531.
    PubMed     Text format    


    October 2015
  65. HARDING E
    Hello. I have cancer. How are you?
    Lancet Oncol. 2015;16:1294.
    PubMed     Text format    


    September 2015
  66. MURRAY AH
    Edinburgh Festival Fringe Round Up.
    Lancet Oncol. 2015;16:1021-2.
    PubMed     Text format    


  67. BROWER V
    Hypofractionated breast radiation reduces acute toxicities.
    Lancet Oncol. 2015;16:e432.
    PubMed     Text format    


  68. KOPANS DB
    The UK Age Trial: screening women in their forties.
    Lancet Oncol. 2015;16:1012-3.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: